Approximately 25% of epileptics' convulsions are inefficiently controlled by currently available remedies; therefore the preparation of new antiepileptic drugs is of great interest. Aryl semicarbazones can be considered a new class of compounds presenting anticonvulsant activity. In addition, they can be orally administered. Semicarbazones derived from aromatic and unsaturated carbonyl compounds as well as from other precursors are reviewed together with their anticonvulsant profile.
INTRODUCTION:
Aryl semicarbazones have been documented to contribute in the design of novel anticonvulsant agents, due to their excellent activity in the maximal electroshock seizure (MES) in both mice and rats and also against clonic seizures induced by pentylenetetrazole (PTZ) in mice, being more active than some conventional AEDs, beside their low neurotoxicity (Rajak, et al., 2009). Semicarbazones have been developed due to their structural dissimilarity from many common monocyclic anticonvulsants containing the dicarboximide function (CONRCO) which may contribute to toxic side effects, so it can be assumed that such novel compounds would not have the side effects seen with many of the currently available anticonvulsant medications (Kadaba 1984) .
A pharmacophoric model has been put forward for antiepileptic activity owing to conformational investigations on prevailing anticonvulsant drugs such as phenytoin, carbamazepine, lamotrigine and phenobarbitone . This semicarbazones based pharmacophoric mode l comprises the following four essential binding sites ( A series of thiosemicarbazones and semicarbazones of arylidene methyl ketones have been prepared and evaluated in the maximal electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ) screens. Compound 1 had an ED 50 of 6.96 mg/kg in the scPTZ test when administered by intraperitoneal route (i.p.) to mice, and a protection index of 10.37 when given orally (Dimmock et al., 1986).
New study (Dimmock et al., 1993) with particular goal of finding compounds with oral activity has been designed with the exclusion of thiosemicarbazones due to its neurotoxicity and lethality (Dimmock et al., 1990; 1991) . Most of the synthesized compounds displayed anticonvulsant activity in MES and scPTZ screens when given to mice by i.p. route. Compound 2 showed the best activity in both models (PI > 5.53 MES and > 2.82 scPTZ). Oral administration of the compounds to rats led to excellent potency in the MES screen while virtually no activity in the scPTZ test was displayed.
As a continuation of the former work, a molecular modeling study has been performed by Dimmock et al. (1995) to develop structure-activity relationship (SAR) of the previously synthesized series of anticonvulsants. Compound 3 was designated the lead compound based on detailed evaluation of its anticonvulsant properties (Dimmock and Baker 1994). The study revealed that the presence of a large hydrophobic group in close proximity to at least two electron-donor atoms is required for MES activity while, for scPTZ a smaller less hydrophobic group should be present near to a minimum of two electrondonor atoms. 
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In order to examine the effect of structure restriction on the anticonvulsant activity, new semicarbazone derivatives of 1-indanone, l-tetralone, 1-benzosuberone, 2-indanone and 2-tetralone, as frozen analogues of the previously synthesized semicarbazones, have been synthesized and tested for its activity by Dimmock et al. (1995) . The potency of compound 4 was 2.98 times that of the acyclic analogue and greater activity than both phenytoin and valproate with a PI of approximately 40. (2000). The first study has been aimed at investigation of the role of the aryl moiety in anticonvulsant activity, thus a new series of 95 (aryloxy)aryl semicarbazones and related compounds has been synthesized, biologically evaluated and many quantitative structure-activity relationships (QSAR) and X-ray crystallographic studies have been performed. Compound 5 was the most active candidate showing activity in both models at 30 mg/kg.
The second study has been particularly oriented towards the hydrogen bonding area. Several compounds have been synthesized following sequential changes in the terminal electron-rich group. It has been revealed that terminal electron-rich groups enhanced the hydrogen bonding capabilities and anticonvulsant properties.
As a part of Dimmocks' research group, Puthucode et al. (1998) have used Dimmocks' compounds 1 and 5 as prototypic molecules for subsequent molecular modification. The study has identified a number of highly promising anticonvulsant semicarbazones derived from aryl, arylidene and aryloxyaryl ketones and aldehydes. Attachment of a 2-naphthyloxy group (compound 6) gave high activity in the rat oral MES screen (ED 50 = 26.8, PI = 18.7). . They have adopted a new concept by attaching another lipophilic moiety at the terminal primary amino function. This modification realized that the terminal primary amino (NH 2 ) group is not essential for anticonvulsant activity and substituting one proton will enhance or at least retain the activity. Investigations in this aspect were started in 1999 through synthesizing a series of 2-nitrobenzaldehyde semicarbazones. The anticonvulsant activity was screened against MES, scPTZ tests in addition to scSTY seizures test which throws light for the interaction with glycine receptors. Compound 7 was the most active in all tests (100 mg/kg MES, 300 mg/kg scPTZ and 30 mg/kg scSTY). They prepared a series of 4-bromophenyl semicarbazones of aliphatic aldehydes. The semicarbazone derivatives were examined in MES, scPTZ and scSTY screens. Semicarbazone 9 showed the greatest activity, being active in all screens (300 mg/kg for MES and scSTY, 100 mg/kg for scPTZ) with very low neurotoxicity and no sedative-hypnotic activity. . They have prepared a series of N-methyl/acetyl 5-(un)-substituted isatin-3-semicarbazones which were subjected to several pharmacological screens (MES, scPTZ, and scSTY). Among the prepared compounds, compound 11 showed broad-spectrum anticonvulsant activity as indicated by its protection in scSTY (300 mg/kg), MES and scPTZ (100 mg/kg) screens. performed another study in order to confirm the essentiality of the hydrogen bonding domain (HBD) and the influence of its isosteric modifications. Therefore, the -NHCO-pharmacophore has been replaced by -OCH 2 -group. Compounds with -NHCO-were found to be the most active in MES, scPTZ and scSTY tests. These compounds were also active in the MES test after oral administration in rats. Compound 12 was found to be the most active in all tests (300 mg/kg in MES, 100 mg/kg in scPTZ and scSTY). On the other hand, compounds with -OCH 2 -isostere were devoid of anticonvulsant activity. This study revealed that the hydrogen bonding domain in semicarbazones, adjacent to the lipophilic aryl ring, is essential for the anticonvulsant activity. The study has shown that introduction of ethyl at the terminal amino group led to increased activity and decreased toxicity. Compound 13 dispayed 100% protection at 300 mg/kg in MES and scPTZ screens. Most of the tested compounds showed protection from seizures in MES and scPTZ screens. Compound 21 was the most active derivative responding in both models at 100 mg/kg. The study revealed that arylsemicarbazones fulfill the essential demands of previously mentioned pharmacophoric model of anticonvulsant and suggested that the anticonvulsant activity was exerted through GABA-mediated mechanism. to prepare a series of 2,6-dimethylphenyl semicarbazones to find a superior compound that would exhibit a broad spectrum of anticonvulsant activity with less or no toxicity. The 2-hydroxybenzaldehyde derivative 22 emerged as a prototype wide spectrum anticonvulsant agent active in five models (MES 100 mg/kg, scPTZ 300 mg/kg, scSTY 30 mg/kg, scPIC 30mg/kg and the kindling model of seizure 100mg/kg) with no neurotoxicity and hepatotoxicity. As well, it increased the 4-aminobutyric acid (GABA) level by 118% and inhibited the GABA transaminase enzyme. The synthesized semicarbazones were effective in MES, scPTZ and scSTY models and additional evidents were found realizing the GABA-mediated mechanism. Compound 24 revealed as the most potent derivative in this series with activity against all tested models (100 mg/kg for MES and scPTZ and 300 mg for scSTY). al., 2006) , have prepared a series of 2,4-dimethoxyphenyl semicarbazones. Among which the propan-2-one derivative 25 was the most active compound (100 mg/kg for MES and scSTY and 300 mg for scPTZ) with no neurotoxicity. In addition, it elevated GABA levels in the midbrain and medulla oblongata regions equipotent to clobazam. ., 2008) . Results revealed that the anticonvulsant activity will be retained when lipophilic distal aryl ring replaced with non-cyclic lipophillic groups (carvone (29) 300 mg/kg for both models and citral (30)100 mg/kg for MES and 300 mg/kg for scPTZ) but not with hydrophilic substituents (levulinic acid). It could be explained through the blood brain barrier (BBB) invasion inability of lipophobic molecules. ., 2006) . The synthesized compounds were evaluated for their anticonvulsant activity by MES, scPTZ, scSTY, and scPIC. The isatin semicarbazone 33 was the most active analog of the series (100 mg/kg in MES and scSTY, and 300 mg/kg scPIC), being more efficacious in most of the tested models than ethosuximide and sodium valporate. The anticonvulsant potential of the synthesized compounds was investigated using MES and scPTZ models. Compound 36 was found to possess significant anticonvulsant activity at 100 mg/kg in both the models. 
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The oxygen isostere of 1,3,4-thiadiazole semicarbazones, 1,3,4-oxadiazole, has been prepared by the same group in 2009 and 2010. A series of 2,5-disubstituted-1,3,4-oxadiazole semicarbazones has been synthesized and evaluated for its anticonvulsant activity. Compound in the first study 38 showed considerable activity in MES at 100 mg/kg and scPTZ at 300 mg/kg without any neurotoxicity. While in the second study, compound 39 displayed broad spectrum anticonvulsant activity (100 mg/kg for MES and scPTZ and 300 mg/kg for scSTY) and absence of neurotoxicity . They have synthesized a number of (4,6-substituteddiphenylpyrimidin-2-yl) semicarbazones. The new compounds have been tested for their anticonvulsant activity against MES and scPTZ. Among these compounds, 44 was found to be remarkably active in both seizure models (30 mg/kg for MES and 100 mg/kg for scPTZ). (1996) . They have utilized the radio-protective activity of dithiolane (Lawa, et al., 1994) to prepare a series of α, ß and ɣ-keto-1,3-dithiolane semicarbazones as protective agents against radio-induced convulsions. Some of the synthesized compounds showed radio-protective effect over 90 min. compound 46 was the most active with respect to duration and number of survivals (90% over 90 min at 400 mg/kg). 
